With allogeneic HCT, the life of the recipient may depend on the timely selection of an acceptable HLA-matched donor. Only a limited number of HLA-matched donors might be identified. Hence, the transplant physician may have to accept a higher risk for transmission of an infectious agent through HCT than would be permitted for routine blood transfusion. This section provides strategies for the HCT physician to minimize transmission of infectious diseases, whenever possible, from donors to recipients. In general, these strategies are dictated by national regulations, and, therefore, ratings are not included.
In addition to recipient safety, clinicians must recognize the role of the donor and the potential impact of the determination of product safety on the donor. [76] [77] [78] [79] Assessment of the donor should include elements related to safety for the donor (for example, uncontrolled hypertension, diabetes mellitus and coronary artery disease) in addition to determination of product safety. A donor may be cleared to donate from a product safety perspective, but be unsuitable because of medical conditions that render the donation unsafe. [76] [77] [78] Owing to these potential risks, individuals who donate must provide informed consent.
Assessment of product safety is complicated by the high frequency of international exchange. A survey by the World Marrow Donor Association found that, in 2006, 3269 (39%) adult products and 829 (40%) umbilical cord blood units were shipped from one country to transplant centers in another country. This robust international activity creates further challenges for ensuring product safety related to regional differences in disease risks, regulatory structures and medical practices.
The desire for HLA tissue matching (which presumably underlies much of the international exchange) results in the potential need to recruit from poorly represented populations. For any given individual, outside of the immediate family, the highest likelihood of an HLA match occurs among persons of the same or similar ethnicity. There is a strong ethical impetus for parity in the likelihood of HLA matching, regardless of the patient's ethnic origins. This may necessitate the recruitment of HCT donors from geographic regions in which endemic conditions would make the residents unsuitable as routine blood or tissue donors.
Regulations
In the United States, the Food and Drug Administration (FDA) issues regulations that cover product safety and donor eligibility, including screening for relevant communicable disease agents and disease, as well as for laboratory and test kit requirements. 80 
Donor conditions affecting product safety
Disorders pertinent to HCT can be categorized according to prevalence and severity. Prevalence concerns the likelihood of the disorder within the potential donor population and may be highly dependent on the donor's geographic location. Severity refers to both the usual consequences of the disorder and the ease of managing those consequences. Highly pertinent disorders [76] [77] [78] 80, 82, 83 include infections caused by HIV, hepatitis B virus, hepatitis C virus, human T-cell leukemia viruses type I and II and the West Nile virus. [84] [85] [86] [87] [88] [89] [90] Other pertinent disorders [76] [77] [78] 82, 83, 91 include transmissible spongiform encephalopathy, [92] [93] [94] [95] Prospective donors with symptoms of active tuberculosis (TB) should be evaluated for that disease, 123, 124 and those with active tuberculosis should not donate until tuberculosis is well controlled (for example, no longer contagious as determined by the donor's primary physician) after appropriate medical therapy. However, transplanting marrow from an untreated, tuberculin-skin-test-positive donor, who has no evidence of active disease, poses no known risk. Screening potential donors for tuberculosis with tuberculin skin tests is not necessary.
Preventing transmission of infections from HCT donors to recipients
All prospective HCT donors should be evaluated to determine their general state of health and whether they pose a risk for transmitting infectious diseases to the recipient. Evaluation of donors is achieved through screening and laboratory testing. [76] [77] [78] 80 Screening and testing of autologous donors is recommended to ensure the safety of laboratory personnel and to prevent cross contamination. If autologous donors are not screened and tested, their autologous units should be specially labeled and handled as if potentially infected. [76] [77] [78] 80 To detect transmissible infections, all HCT donor collection site personnel should follow up-to-date published guidelines and standards for donor screening and testing.
Complete donor screening, which includes history, physical examination and review of medical records, must be performed within 6 months preceding donation. Before each donation procedure, screening must be repeated or updated. Abbreviated screening may be used if complete screening has been performed within the previous 6 months. 80, 83 Abbreviated screening is an inquiry about any changes in history, risk factors or physical findings. This practice is critical because of the fact that if new risk findings have developed, the potential donor might require further evaluation or deferral. When the donor is 1 month of age or younger, including all umbilical cord blood donations, the infant's mother should be screened. 80, 83 Donor history includes a direct questioning of the donor (which can be carried out over the telephone), with documentation of all donor responses, review of available medical records and completion of a risk factor questionnaire (for example, the National Marrow Donor Program questionnaire).
125 Physical examination of the donor is targeted to detect stigmata associated with transfusion-transmissible disease or high-risk activities.
In addition to donor screening, laboratory testing must be performed to assess for relevant infectious diseases. In the United States, for lymphocyte and umbilical cord blood donations, a specimen for testing must be obtained within 7 days before or after donation. For PBSC and BM donations, the specimen may be obtained up to 30 days before donation. In the European Union, the testing specimen must be obtained at the time of donation or within 7 days after donation unless the product can be stored. If storage is possible, the sample may be obtained up to 30 days before donation; however, this invokes a further requirement for retesting of the donor 180 days or more after donation. However, retesting is not required if nucleic acid testing for HIV, hepatitis C virus and hepatitis B virus is included in the initial specimen. As in the United States, for PBSCs or BM that will not be stored, the specimen may be obtained up to 30 days before donation and there is no requirement for retesting.
In the United States, positive results on screening tests are used for the determination of disease risk, irrespective of the results obtained with confirmatory tests. The sole exception is testing for syphilis, wherein a syphilis-specific test is used for determining eligibility.
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Use of potentially unsafe products
Oversight by governments and unrelated donor registries generally precludes the use of a volunteer unrelated donor at risk for infectious diseases transmissible by HCT. [78] [79] [80] 82, 83 Whether to select a related donor who is at risk for or who has an infectious disease transmissible by HCT should be determined on a case-by-case basis and is the final responsibility of the HCT physician. If the only possible donor is at risk for, or known to have, infection with a bloodborne pathogen, but the patient is likely to succumb rapidly from his or her disease if an HCT is not received, the physician must carefully weigh the risks and benefits of using potentially infected donor cells. No person should be denied a potentially life-saving HCT procedure solely on the basis of risk for an infectious disease. However, HCT physicians should avoid transplanting any hematopoietic cell product from an infected or infectious donor unless no other stem cell product can be obtained and the risk for death if transplantation is not performed is deemed to be higher than that for morbidity or death from the infection that may be transmitted. If the HCT physician judges that the circumstances of the case justify the use of such a product, the following should be noted in the recipient's chart:
Knowledge and authorization of the recipient's HCT physician regarding the potential for transmission of an infectious agent during HCT; and informed consent from the recipient or recipient's legal guardian acknowledging the possible transmission of an infectious agent during transplantation.
Subsequently, the HCT physician should include the infectious agent in the differential diagnosis of any illness that the HCT recipient experiences so that the infection, if transmitted, can be diagnosed early and treated preemptively, if possible.
Infectious products (except those in which CMV seropositivity is the only evidence of infection) should be labeled as being a biohazard or as untested for biohazards, as applicable. A warning label should list all disease agents or diseases for which the donor has shown reactive test results. Tissue intended for autologous use should be labeled 'For Autologous Use Only-Use Only for (Patient's Name).' Safe handling, processing and storage of donated units Personnel of donation, collection or transplantation centers, as well as of cell-processing laboratories and courier services, should follow current standards for detecting and preventing extrinsic bacterial and fungal contamination of collected stem cell units at the collection site, during processing and transportation, as well as at the transplant center.
126-141 Current, comprehensive discussions of these issues are detailed in the FDA 'Good Tissue Practice ' regulations, 142 in the European Commission regulations 81 and in international standards established by professional organizations. 76, 77, 143 
